Radiomics
    Insight-based
    decision making

    Diseases and
    therapeutic areas

    Discover
    where we are active

    Industry
    and Pharma

    Discover
    our services

    Healthcare
    professionals

    Discover
    our products

    Scientific
    researchers

    Discover
    our expertise

    About Radiomics

    Radiomics is a next generation Liege-based imaging research organization built upon the unparallel experience of its founders, pioneers of the radiomics science.
     
    Radiomics focuses on AI powered healthcare, with a unique expertise in Radiomics, Deep Learning & Federated Learning applied to oncology and other therapeutic areas. Through our proprietary advanced image analysis technology, we aim to unravel the gold mine of hidden data information embedded in standard medical images.
     
    Our final goal is to support insight-based decision making for optimizing pharmaceutical and biotech companies’ clinical trials and drug development studies and for providing clinicians with a patient-centered approach based on personalized medicine. With this aim, Radiomics’ R&D team is continuously working on new solutions, in collaboration with multiple national and international partners.
    Read more

    We can help you

    optimize

    Optimize

    Your clinical trials (in terms of costs and time)

    detect

    Detect

    The subtlest signals of drugs efficacy and safety risk
    facilitate

    Facilitate

    Your crucial
    go / no-go
    decisions
    identify

    Identify

    Patients likely to respond to your treatment
    strenghten

    Strengthen

    Your points
    in pay for outcome scenarios

    Why Radiomics

    Experience

    Our scientists and clinicians are the ones who invented radiomics and have unparalleled experience and international recognition in this AI field.

    Outreach

    Radiomics has clients and partners in the EU, the US, Africa and Australia. Permanent presence in North America and China are in our plans for the near future.

    IP Portfolio

    Radiomics' comprehensive IP portfolio includes both granted and pending international (EU/US) patents.

    People

    Radiomics' team is composed of a multicultural and multidisciplinary set of people, specialized in a broad range of domains always enthusiastic in addressing clients and partner's needs. 

    Publications

    Radiomics has numerous publications in high impact journals such as Nature Reviews, Clinical Oncology, Annals of Oncology and many more. 

    Latest news

    press
    • November 25th, 2021

    Radiomics announces the strategic support of OncoDNA in its prospective clinical trial SALMON

    The two Belgian companies will work towards a better understanding of non-small cell lung cancer biology and characterization of the tumors using of AI technology

    Read more
    press
    • November 17th, 2021

    Radiomics secures €6 Million to fund new projects and initiatives

    Radiomics announced that it has secured €6 Million in a pre-series B funding led by its main investors (Epimede and Noshaq) and backed by its original funders, its management team, some banks and non-dilutive financing from Walloon Regional Authorities in support of R&D Projects.

    Read more
    press
    • November 9th, 2021

    Kazia Therapeutics and Radiomics collaborate in development of novel therapy

    Radiomics, AI-powered imaging research organization, and Kazia Therapeutics, Australian oncology company developing innovative, high-impact drugs for cancer, announced that they have entered into a partnership to enhance imaging insights for the clinical development of EVT801.

    Read more
    Read our latest news
    Share this page with your network
    radiomics logo
    Go to
    diseases and therapeutic areas
    industry & pharma
    healthcare professionals
    scientific researchers & academia
    Contact
    Clos Chanmurly 13
    4000 Liège
    Belgium
    BE.0662.719.440
    [email protected]
    Design:Nelson